Advertisement
Advertisement
U.S. Markets close in 4 hrs 45 mins
Advertisement
Advertisement
Advertisement
Advertisement

Vaccitech plc (VACC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.3450-0.0150 (-0.64%)
As of 10:58AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3600
Open2.4400
Bid2.2900 x 3200
Ask2.4000 x 1200
Day's Range2.3100 - 2.4400
52 Week Range2.0800 - 12.7100
Volume19,789
Avg. Volume38,300
Market Cap81.792M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.1600
Earnings DateAug 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.75
  • GlobeNewswire

    Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

    OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic immunotherapies for celiac disease and other autoimmune diseases on Monday, November 28, 2022 at 4:30 pm ET. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infec

  • Simply Wall St.

    Vaccitech Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

    Vaccitech ( NASDAQ:VACC ) Third Quarter 2022 Results Key Financial Results Revenue: US$6.17m (up by US$6.15m from 3Q...

  • GlobeNewswire

    Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer. “This has been a very exciting qua

Advertisement
Advertisement